Back to results
US 7,384,644 B2Granted
Modified Vaccinia Ankara virus variant
AssigneeBavarian Nordic A/S
InventorsPaul Chaplin, Paul Howley, Christine Meisinger-Henschel
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBavarian Nordic A/S
InventorsPaul Chaplin, Paul Howley, Christine Meisinger-Henschel
Estimating the term…
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by induction of protective immunity against a lethal vaccinia virus infection in a mouse, whereby the effective amount of the MVA-BN virus, or a derivative thereof, required to confer said immunity is less than the effective amount of MVA-575 required to render said mouse immune to a lethal vaccinia virus infection, and/or the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
A Modified Vaccinia virus Ankara (MVA) strain MVA-BN, deposited at the European Collection of Cell Cultures (ECACC), Salisbury (UK) under number V00083008 and derivatives thereof, wherein said strains are characterized by having at least one of the following properties:
Dependencies are inferred from the claim text.